Insider Buying: Enovis (NYSE:ENOV) Director Acquires $24,506.96 in Stock

Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor acquired 874 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were bought at an average price of $28.04 per share, for a total transaction of $24,506.96. Following the acquisition, the director directly owned 34,117 shares of the company’s stock, valued at approximately $956,640.68. This trade represents a 2.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Enovis Stock Up 0.6%

Shares of ENOV stock traded up $0.17 on Monday, reaching $27.85. 1,258,195 shares of the company were exchanged, compared to its average volume of 1,879,055. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08. The company has a 50-day moving average of $20.71 and a 200-day moving average of $23.25. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -3.02 and a beta of 1.31. Enovis Corporation has a one year low of $16.70 and a one year high of $31.67.

Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. During the same period in the previous year, the company posted $0.75 EPS. The firm’s revenue was up 1.8% compared to the same quarter last year. Analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ENOV. Citigroup reiterated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Citizens Jmp lowered their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Wells Fargo & Company raised their price objective on shares of Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus price target of $38.62.

View Our Latest Report on Enovis

Hedge Funds Weigh In On Enovis

Several large investors have recently bought and sold shares of the stock. State of Tennessee Department of Treasury lifted its stake in Enovis by 20.7% during the 3rd quarter. State of Tennessee Department of Treasury now owns 21,216 shares of the company’s stock valued at $388,000 after acquiring an additional 3,643 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Enovis by 54.2% in the 3rd quarter. Marshall Wace LLP now owns 454,094 shares of the company’s stock worth $8,296,000 after acquiring an additional 159,649 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Enovis in the 3rd quarter worth $2,244,000. First Trust Advisors LP grew its stake in shares of Enovis by 60.2% in the 3rd quarter. First Trust Advisors LP now owns 100,117 shares of the company’s stock worth $1,829,000 after acquiring an additional 37,636 shares in the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in shares of Enovis by 66.0% in the third quarter. Public Sector Pension Investment Board now owns 328,148 shares of the company’s stock valued at $6,223,000 after purchasing an additional 130,436 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Articles

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.